AKT1 and neoplasm: Moreover, other pathways are also involved in this tumor progression such as PI3K/AKT/mTOR pathway activation in 30–40% of patients, DDR gene alterations in 20–30% of patients, cell cycle alterations in 20% of patients, or the Wnt signaling pathway in 18% of patients [1].